Arcutis Biotherapeutics Announces Closing of Underwriters’ Over-Allotment Option in Connection with Public Offering of Common Stock - Seite 2
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Arcutis - Bioscience, applied to the skin.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.
Forward Looking Statements
This press release contains "forward-looking" statements. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause Arcutis’ actual results,
levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on
our forward-looking statements. Risks and uncertainties that may cause Arcutis’ actual results to differ include risks and uncertainties associated with the effect of changing economic conditions,
risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, and Arcutis’ ability to defend its intellectual property. Arcutis’ business
could be affected by a number of other factors, including the risk factors discussed in the preliminary prospectus supplement relating to the offering and the documents incorporated by reference
therein, which include Arcutis’ Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. The forward-looking statements contained in this press release speak only as of the date
hereof and Arcutis cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Arcutis disclaims any obligation, and does not undertake to update
or revise any forward-looking statements in this press release.
Lesen Sie auch
Contact:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
harmstrong@arcutis.com
805-418-5006, Ext. 740